ArticleScientific reports2025
Investigation of the loading and release behavior of paracetamol, mesalazine, and carbamazepine utilizing Cu-and Zn(BDC) MOFs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, Cu(BDC) and Zn(BDC) metal organic frameworks were synthesized using an ultrafast ultrasound-assisted method at room temperature for loading and releasing the drugs paracetamol, carbamazepine, and mesalazine. The synthesized MOFs were characterized and identified using FT-IR, XRD, TGA, SEM, and UV-Vis analyses, and the characterization data were complemented by BET and EDX surface area measurements. BET results confirmed the porous structure of the MOFs, and EDX confirmed the complete removal of CTAB and successful drug incorporation. The loading behavior of the MOFs were evaluated using TGA, which showed efficiencies of 21.3% (paracetamol), 20.8% (carbamazepine), and 33.1% (mesalazine) for the Cu(BDC) MOF, while 25.2%, 61.1% and 36.4% were achieved for the same drugs using the Zn(BDC) MOF. Drug release studies were performed in phosphate buffer solution at 37°C, simulating physiological conditions. The results showed that the ultrasonically synthesized Cu-BDC and Zn-BDC MOFs possess stable porosity, effective drug loading capability, and distinct release behaviors. This comparison highlights their potential as tunable platforms for controlled drug delivery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.